Stock Scorecard
Stock Summary for Design Therapeutics Inc (DSGN) - $9.95 as of 2/6/2026 9:07:04 AM EST
Total Score
9 out of 30
Safety Score
23 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for DSGN
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for DSGN
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for DSGN
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for DSGN
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for DSGN (23 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 0 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for DSGN
Financial Details for DSGN
Company Overview |
|
|---|---|
| Ticker | DSGN |
| Company Name | Design Therapeutics Inc |
| Country | USA |
| Description | Design Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Carlsbad, California, focused on pioneering therapies for degenerative disorders associated with nucleotide repeat expansions, such as Friedreich's ataxia. The company is advancing a proprietary pipeline of small-molecule drug candidates aimed at addressing the underlying genetic mechanisms of these diseases to restore normal cellular function and improve patient outcomes. With a commitment to tackling significant unmet medical needs, Design Therapeutics is strategically positioned to impact the biopharmaceutical landscape, especially in the niche of rare genetic diseases. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/9/2026 |
Stock Price History |
|
| Last Day Price | 9.95 |
| Price 4 Years Ago | 10.26 |
| Last Day Price Updated | 2/6/2026 9:07:04 AM EST |
| Last Day Volume | 246,779 |
| Average Daily Volume | 346,087 |
| 52-Week High | 10.97 |
| 52-Week Low | 2.60 |
| Last Price to 52 Week Low | 282.69% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 23.21 |
| Sector PE | 34.82 |
| 5-Year Average PE | -10.60 |
| Free Cash Flow Ratio | 38.27 |
| Industry Free Cash Flow Ratio | 12.52 |
| Sector Free Cash Flow Ratio | 33.33 |
| Current Ratio Most Recent Quarter | 18.71 |
| Total Cash Per Share | 0.26 |
| Book Value Per Share Most Recent Quarter | 3.51 |
| Price to Book Ratio | 2.85 |
| Industry Price to Book Ratio | 53.70 |
| Sector Price to Book Ratio | 53.77 |
| Price to Sales Ratio Twelve Trailing Months | 22,642.01 |
| Industry Price to Sales Ratio Twelve Trailing Months | 21.10 |
| Sector Price to Sales Ratio Twelve Trailing Months | 17.66 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 56,964,000 |
| Market Capitalization | 566,791,800 |
| Institutional Ownership | 59.33% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 25.84% |
| Reported EPS 12 Trailing Months | -1.19 |
| Reported EPS Past Year | -0.95 |
| Reported EPS Prior Year | -0.88 |
| Net Income Twelve Trailing Months | -67,446,000 |
| Net Income Past Year | -49,588,000 |
| Net Income Prior Year | -66,862,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 15,088,000 |
| Total Cash Past Year | 22,563,000 |
| Total Cash Prior Year | 21,200,000 |
| Net Cash Position Most Recent Quarter | 15,088,000 |
| Net Cash Position Past Year | 22,563,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 242,097,000 |
| Total Stockholder Equity Prior Year | 277,687,000 |
| Total Stockholder Equity Most Recent Quarter | 199,720,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -52,411,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.92 |
| Free Cash Flow Past Year | -43,445,000 |
| Free Cash Flow Prior Year | -58,816,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 5.23 |
| 20-Day Bollinger Middle Band | 8.35 |
| 20-Day Bollinger Upper Band | 11.46 |
| Beta | 1.64 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 2/6/2026 9:40:59 PM EST |